Page 27 - Ongoing Development News Today

Share this article Share this article ResearchAndMarkets.coms offering. The fast pace of cancer prevalence and mortality rate across the globe has led to an increasing concern as well as recognition that the specific disease requires attention by the researchers. In the past few years, the type of research activities that have been conducted for cancer disease has moved several laboratory findings to the commercial world. In one of the scenarios, development of cancer biological toxins is a fo...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Gilead  and  Galapagos  announce  New  Commercialization  and  Development  Agreement  for  ... Galapagos NVDecember 15, 2020 GMT -- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Re...

Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis in the U.S. Following FDA Type A Meeting — — Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 — — Galapagos to Assume Responsibility for Majority of Ongoing Clinical Trials; Gilead will Pay Ga...

Gilead Sciences, Inc.: Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca (Filgotinib) -- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 -- -- Galapagos to Assume Responsibility for Majority of ...

Share: -- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 -- -- Galapagos to Assume Responsibility for Majority of Ongoing Clinical Trials -- -- Gilead will Pay Galapagos €160 million to Support Ongoing Development and Accelerated Co...

Galapagos NV: Gilead and Galapagos announce New Commercialization and Development Agreement for Jyseleca (filgotinib) -- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 -- -- Galapagos to Assume Responsibility for Majority of Ongoing C...

Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib) -- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 -- -- Galapagos to Assume Responsibility for Majority of Ongoing Clini...

Message : Required fields -- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 -- -- Galapagos to Assume Responsibility for Majority of Ongoing Clinical Trials -- -- Gilead will Pay Galapagos €160 million to Support Ongoing Development...

Gilead  and  Galapagos  announce  New  Commercialization  and  Development  Agreement  for  Jyseleca®  (filgotinib)   -- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 -- -- Galapagos to Assume Responsibility for Majorit...